St. John's Wort (Hypericum perforatum) for the Treatment of Major Depressive Disorder: A Systematic Review of Clinical Evidence

Abstract

Introduction: Major Depressive Disorder (MDD) is a significant global health burden. St. John's Wort (SJW) is a popular herbal remedy for depression, but its efficacy and safety compared to standard antidepressants remain debated. This review systematically assesses the evidence for SJW in treating MDD.

Methods: We searched MEDLINE, Embase, and PsycINFO for RCTs comparing SJW extracts to placebo or synthetic antidepressants in adults diagnosed with MDD. The primary outcome was the change in depression severity scores (e.g., HAM-D). Study quality was assessed using the Jadad scale.

Results: Thirty-five RCTs with 6,993 patients were included. In comparisons with placebo, SJW was consistently superior in reducing depression symptoms (Relative Risk [RR] for response = 1.55, 95% CI: 1.42 to 1.69). When compared to standard antidepressants (SSRIs and tricyclics), SJW demonstrated comparable efficacy (RR = 1.01, 95% CI: 0.95 to 1.07) but with significantly fewer side effects and lower dropout rates.

Discussion: The evidence indicates that specific extracts of St. John's Wort are effective for the short-term treatment of mild to moderate MDD and have a more favorable side-effect profile than older and newer generation antidepressants. The potential for drug interactions, particularly with cytochrome P450 substrates, is a significant clinical consideration.

Conclusion: St. John's Wort is a viable therapeutic option for mild to moderate depression, offering efficacy comparable to standard antidepressants with better tolerability.